Why Moderna's Stock Is Trading Higher Today

Moderna, Inc. MRNA shares are trading higher after analysts at multiple firms raised their price targets on the stock. The company has attracted investor interest recently, as it is working on a coronavirus (COVID-19) vaccine.

Morgan Stanley maintained an Overweight rating and raised its price target from $30 to $37.

Oppenheimer maintained an Outperform rating and raised its price target from $31 to $43.

Moderna shares were trading up 10.65%, hitting a 52-week high of $38.35 on Wednesday. The stock has a 52-week low of 11.54.